Literature DB >> 16865530

Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation?

Heng-Ju Chen1, Yu-Hung Lin, Bih-Chwen Hsieh, Kok-Min Seow, Jiann-Loung Hwang, Chii-Ruey Tzeng.   

Abstract

PURPOSE: This study was performed to evaluate whether a lower dose (0.2 mg) of cetrorelix would prevent premature LH surge in patients undergoing controlled ovarian hyperstimulation.
METHODS: Controlled ovarian hyperstimulation was carried out in 45 patients, starting on menstrual cycle day 3 with recombinant FSH (r-FSH), and a cetrorelix of 0.2 mg was administered from day 5 evening of ovarian stimulation until the day before hCG injection.
RESULTS: There was a statistically significant decrease in serum LH level one day after the first cetrorelix injection and on the day of hCG administration. Serum LH concentrations were maintained constantly low during the follicular phase with no premature LH surge occurring in any of the patients. Clinical pregnancy was achieved for 18 women (40%), with one of these experiencing intrauterine fetal death before 12 week' gestation.
CONCLUSION: This study demonstrates that a daily dose of cetrorelix 0.2 mg is able to prevent premature LH surge.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16865530      PMCID: PMC3506367          DOI: 10.1007/s10815-006-9054-0

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  16 in total

1.  Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.

Authors:  C Albano; J Smitz; M Camus; H Riethmüller-Winzen; A Van Steirteghem; P Devroey
Journal:  Fertil Steril       Date:  1997-05       Impact factor: 7.329

2.  The role of gonadotropin-releasing hormone in murine preimplantation embryonic development.

Authors:  F Raga; E M Casañ; J Kruessel; Y Wen; F Bonilla-Musoles; M L Polan
Journal:  Endocrinology       Date:  1999-08       Impact factor: 4.736

Review 3.  Extrapituitary effects of GnRH antagonists in assisted reproduction: a review.

Authors:  J B Engel; H Riethmüller-Winzen; K Diedrich
Journal:  Reprod Biomed Online       Date:  2005-02       Impact factor: 3.828

4.  GnRH antagonist in assisted reproduction: a Cochrane review.

Authors:  Hesham Al-Inany; Mohamed Aboulghar
Journal:  Hum Reprod       Date:  2002-04       Impact factor: 6.918

5.  High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles.

Authors:  S Kol; A Lightman; T Hillensjo; P Devroey; B Fauser; B Tarlatzis; B Mannaerts; J Itskovitz-Eldor
Journal:  Hum Reprod       Date:  1999-09       Impact factor: 6.918

6.  Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages.

Authors:  R Felberbaum; T Reissmann; W Küpker; S Al-Hasani; O Bauer; T Schill; C Zoll; C Diedrich; K Diedrich
Journal:  J Assist Reprod Genet       Date:  1996-03       Impact factor: 3.412

7.  A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.

Authors: 
Journal:  Hum Reprod       Date:  1998-11       Impact factor: 6.918

8.  Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.

Authors:  K Diedrich; C Diedrich; E Santos; C Zoll; S al-Hasani; T Reissmann; D Krebs; D Klingmüller
Journal:  Hum Reprod       Date:  1994-05       Impact factor: 6.918

9.  Expression of gonadotropin-releasing hormone (GnRH) gene in human uterine endometrial tissue.

Authors:  K W Dong; K Marcelin; M I Hsu; C M Chiang; G Hoffman; J L Roberts
Journal:  Mol Hum Reprod       Date:  1998-09       Impact factor: 4.025

10.  Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles.

Authors:  Jiann-Loung Hwang; Lee-Wen Huang; Bih-Chwen Hsieh; Yieh-Loong Tsai; Shih-Chia Huang; Chin-Yu Chen; Mei-Ling Hsieh; Pei-Hsin Chen; Yu-Hung Lin
Journal:  Hum Reprod       Date:  2003-01       Impact factor: 6.918

View more
  3 in total

1.  Assessing the optimal dose for Cetrorelix in Chinese women undergoing ovarian stimulation during the course of IVF-ET treatment.

Authors:  Qiaohong Lai; Jun Hu; Dan Zeng; Juan Hu; Fuying Cai; Fei Yang; Cai Chen; Xiaoyu He; Ping Yang; Qilin Yu; Shu Zhang; Jun-Fa Xu; Cong-Yi Wang
Journal:  Am J Transl Res       Date:  2013-12-01       Impact factor: 4.060

2.  Cessation of gonadotropin-releasing hormone antagonist on triggering day: an alternative method for flexible multiple-dose protocol.

Authors:  Hye Jin Chang; Jung Ryeol Lee; Byung Chul Jee; Chang Suk Suh; Seok Hyun Kim
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

3.  GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve.

Authors:  Huihui Xu; Shen Zhao; Xinxing Gao; Xian Wu; Lan Xia; Dan Zhang; Jian Li; Aijun Zhang; Bufang Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-14       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.